THE SAFETY AND EFFICACY OF CONVERSION FROM CALCINEURIN INHIBITORS TO mTOR INHIBITORS IN STABLE KIDNEY TRANSPLANT RECIPIENTS

被引：0
|
作者：
Asanga, Abeyaratne [1 ]
Michael, Collins [1 ]
Kym, Bannister [1 ]
Graeme, Russ [1 ]
机构：
[1] Royal Adelaide Hosp, Renal & Transplantat Unit, Cent No Adelaide Renal & Transplantat Serv, Adelaide, SA, Australia
来源：
IMMUNOLOGY AND CELL BIOLOGY | 2012年 / 90卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：A1 / A1
页数：1
相关论文
共 50 条
  • [31] Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney function
    Hina Khalid
    Muhammad Mazhar Fareed
    Thomas Dandekar
    Sergey Shityakov
    International Urology and Nephrology, 2024, 56 : 1403 - 1414
  • [32] Long-Term Redistribution of Peripheral Lymphocyte Subpopulations after Switching from Calcineurin to mTOR Inhibitors in Kidney Transplant Recipients
    Llinas-Mallol, Laura
    Redondo-Pachon, Dolores
    Raich-Regue, Dalia
    Perez-Saez, Maria Jose
    Yelamos, Jose
    Duran, Xavier
    Faura, Anna
    Lopez-Botet, Miguel
    Pascual, Julio
    Crespo, Marta
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [33] LATE CONVERSION FROM CALCINEURIN INHIBITORS TO BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS HAS A SIGNIFICANT BENEFICIAL IMPACT ON GLYCEMIC PARAMETERS
    Terrec, F.
    Jouve, T.
    Naciri-Bennani, H.
    Benhamou, P. Y.
    Malvezzi, P.
    Janbon, B.
    Giovannini, D.
    Rostaing, L.
    Noble, J.
    TRANSPLANT INTERNATIONAL, 2020, 33 : 17 - 17
  • [34] A Systematic Review of Conversion From Calcineurin Inhibitor to Mammalian Target of Rapamycin Inhibitors for Maintenance Immunosuppression in Kidney Transplant Recipients
    Lim, W. H.
    Eris, J.
    Kanellis, J.
    Pussell, B.
    Wiid, Z.
    Witcombe, D.
    Russ, G. R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (09) : 2106 - 2119
  • [35] Cancer and mTOR Inhibitors in Transplant Recipients
    de Fijter, Johan W.
    TRANSPLANTATION, 2018, 102 (02) : S60 - S70
  • [36] Cancer and mTOR Inhibitors in Transplant Recipients
    de Fijter, Johan W.
    TRANSPLANTATION, 2017, 101 (01) : 45 - 55
  • [37] Conversion from Calcineurin Inhibitors to mTOR Inhibitors in Renal Transplantation: A Single Centre Experience
    Oguz, Ebru Gok
    Yildirim, Tolga
    Merhametsiz, Ozgur
    Yayar, Ozlem
    Gursoy, Guner Karaveli
    Spulat, Ayhan Ha
    Ercan, Zafer
    Akoglu, Hadim
    Akdag, Seyit Ibrahim
    Ayli, Deniz
    TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, 2014, 23 (03): : 229 - 233
  • [38] Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Zeng, Jun
    Zhong, Qiang
    Feng, Xiaobing
    Li, Linde
    Feng, Shijian
    Fan, Yu
    Song, Turun
    Huang, Zhongli
    Wang, Xianding
    Lin, Tao
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [39] Safety and Efficacy of Belatacept in Heart Transplant Patients with Chronic Kidney Disease or Intolerance to Calcineurin Inhibitors
    Yehya, A.
    Ham, P.
    Pearston, A.
    Ingemi, A.
    Cohan, D.
    Mandel, J.
    Badiye, A.
    Herre, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S517 - S517
  • [40] Belatacept in kidney transplant recipients switched from calcineurin inhibitors: results on renal function and safety after 6 months
    Bardo, P.
    Berdougo, B.
    Rouimi, E.
    Grimbert, P.
    Astier, A.
    Paul, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (06) : 1301 - 1302
12345